Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1983 Jul;53(1):109-14.

Further evidence for T cell abnormalities in chronic lymphocytic leukaemia of the B cell type

Further evidence for T cell abnormalities in chronic lymphocytic leukaemia of the B cell type

F Herrmann et al. Clin Exp Immunol. 1983 Jul.

Abstract

Functional properties were studied in the purified T cell fraction of patients with chronic lymphocytic leukaemia of the B cell type (B-CLL). This analysis included the evaluation of T suppressor activity when investigated patients' T cells were co-cultured together with allogenic normal B and OKT4 enriched T cells in the presence of pokeweed mitogen (PWM). The Ig secreting cells (ISC) were assessed in a reverse haemolytic plaque assay (RHPA). Antibody-dependent cytotoxicity (ADCC) and natural killer activity (NK) were determined in a 51Cr release assay. Furthermore, purified T cells reactive with the monoclonal antibody HNK1, known to recognize most effector cells in ADCC and NK, were enumerated using an indirect immunofluorescence. Our results revealed increased T suppressor cell activity and markedly deficient NK activity in peripheral blood lymphocytes (PBL), T cell and T gamma cell fractions from B-CLL patients, whereas ADCC potential was only increased in T cells and T gamma cells. Accordingly, T cells were recognized by HNK1 in greater numbers in B-CLL patients than in healthy subjects. Our data suggest that there may be a link between our findings and the hypogammaglobulinaemia as well as the increased incidence of second neoplasias reported in CLL.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Lancet. 1973 Jan 20;1(7795):126-9 - PubMed
    1. Lancet. 1974 Nov 23;2(7891):1230-3 - PubMed
    1. JAMA. 1975 Apr 21;232(3):267-9 - PubMed
    1. Blood. 1975 Aug;46(2):219-34 - PubMed
    1. J Immunol. 1977 Jan;118(1):355-61 - PubMed

Publication types

Substances

LinkOut - more resources